Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneFIX prophylaxis and bleed treatment in previously treated hemophilia B patients
2020-004430-38Phase 4
- Sponsor
- Pfizer
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Pfizer. Primary endpoint: Proportion of subjects who develop factor IX inhibitor.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2020-004430-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004430-38.